AKROAkero Therapeutics, Inc.

Nasdaq akerotx.com


$ 24.00 $ -0.64 (-2.6 %)    

Friday, 14-Jun-2024 15:59:57 EDT
QQQ $ 479.30 $ 2.47 (0.52 %)
DIA $ 386.46 $ -0.42 (-0.11 %)
SPY $ 542.65 $ 0.33 (0.06 %)
TLT $ 94.67 $ 0.79 (0.84 %)
GLD $ 215.76 $ 2.76 (1.3 %)
$ 23.98
$ 24.19
$ 23.98 x 200
$ 24.00 x 100
$ 23.47 - $ 24.23
$ 11.25 - $ 56.66
559,513
na
1.42B
$ 0.30
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-10-2024 03-31-2024 10-Q
2 02-29-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-11-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-17-2023 12-31-2022 10-K
7 11-04-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-06-2022 03-31-2022 10-Q
10 02-25-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-13-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-16-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 08-12-2020 06-30-2020 10-Q
17 05-13-2020 03-31-2020 10-Q
18 03-16-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-12-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cantor-fitzgerald-reiterates-overweight-on-akero-therapeutics

Cantor Fitzgerald analyst Prakhar Agrawal reiterates Akero Therapeutics (NASDAQ:AKRO) with a Overweight.

 wolfe-research-initiates-coverage-on-akero-therapeutics-with-outperform-rating

Wolfe Research analyst Andy Chen initiates coverage on Akero Therapeutics (NASDAQ:AKRO) with a Outperform rating.

 akero-therapeutics-begins-phase-3-study-on-efruxifermin-for-liver-disease-treatment

Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serio...

 hc-wainwright--co-reiterates-buy-on-akero-therapeutics-maintains-50-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Akero Therapeutics (NASDAQ:AKRO) with a Buy and maintains $50 price target.

 reported-saturday-akero-therapeutics-presented-data-highlighting-the-efficacy-and-safety-of-efx-in-patients-with-mash-at-easl-congress

A late-breaking oral presentation will feature 96-week data from HARMONY, a Phase 2b study evaluating the efficacy and safety o...

 whats-going-on-with-fattly-liver-disease-focused-madrigal-pharmaceuticals-sagimet-biosciences-shares-on-wednesday

Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress ...

 evercore-isi-group-maintains-outperform-on-akero-therapeutics-lowers-price-target-to-38

Evercore ISI Group analyst Liisa Bayko maintains Akero Therapeutics (NASDAQ:AKRO) with a Outperform and lowers the price tar...

 canaccord-genuity-maintains-buy-on-akero-therapeutics-lowers-price-target-to-56

Canaccord Genuity analyst Edward Nash maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and lowers the price target from...

 hc-wainwright--co-reiterates-buy-on-akero-therapeutics-maintains-50-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Akero Therapeutics (NASDAQ:AKRO) with a Buy and maintains $50 price target.

 akero-therapeutics-q1-eps-090-beats-095-estimate

Akero Therapeutics (NASDAQ:AKRO) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate of $(...

 b-of-a-securities-reinstates-neutral-on-akero-therapeutics-announces-30-price-target

B of A Securities analyst Alexandria Hammond reinstates Akero Therapeutics (NASDAQ:AKRO) with a Neutral and announces $30 pr...

 akero-therapeutics-publishes-phase-2b-symmetry-cohort-d-study-in-clinical-gastroenterology-and-hepatology

As reported previously, the addition of EFX to GLP-1 receptor agonist therapy had a safety and tolerability profile comparable ...

 akero-therapeutics-prices-public-offering-of-11m-common-stock-at-29share

The comnay announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a public offeri...

 ubs-maintains-buy-on-akero-therapeutics-raises-price-target-to-42

UBS analyst Eliana Merle maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and raises the price target from $39 to $42.

 hc-wainwright--co-maintains-buy-on-akero-therapeutics-raises-price-target-to-50

HC Wainwright & Co. analyst Ed Arce maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and raises the price target fr...

 akero-therapeutics-begins-public-offering-of-300m-of-shares-of-its-common-stock

All of the shares in the proposed offering are being offered by Akero Therapeutics. In addition, Akero Therapeutics intends to ...

 why-bitdeer-technologies-shares-are-trading-higher-by-10-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported prelimina...

 akero-therapeutics-stock-is-soaring-monday---heres-why

Akero Therapeutics success in HARMONY Phase 2b study for efruxifermin. EFX demonstrated sustained efficacy and well-tolerance, ...